分类: health

  • Ebola risk now at highest level in DR Congo, says WHO

    Ebola risk now at highest level in DR Congo, says WHO

    On Friday, the World Health Organization announced it has upgraded the Ebola outbreak risk assessment in the Democratic Republic of the Congo (DRC) to the highest possible level — very high — as confirmed cases and deaths from the rare virus strain continue to climb faster than response teams can contain.

    Current official figures from the WHO place the count of confirmed Ebola cases at 82, with seven confirmed fatalities. When including suspected cases, those numbers jump to nearly 750 potential infections and 172 suspected deaths. WHO leaders emphasize that the true size of the epidemic is already far larger than the confirmed case count, as the virus circulated undetected for weeks before being identified.

    The outbreak is caused by the Bundibugyo strain of Ebola, an uncommon variant that has no specifically approved vaccines or antiviral treatments currently available to combat it. This critical gap in medical countermeasures has forced the global health body to fast-track testing of existing experimental treatments to assess their effectiveness against the strain.

    Speaking to reporters at WHO headquarters in Geneva, director-general Tedros Adhanom Ghebreyesus described the situation as deeply worrisome and uniquely challenging. Response teams are working in highly insecure regions of the country, scrambling to track the virus’s spread, trace close contacts of infected people, and establish full outbreak control measures. “We know the epidemic in DRC is much larger than the confirmed cases,” Tedros said.

    The outbreak is centered in the northeastern DRC’s Ituri province, where more than 1,400 contacts are currently being monitored by health teams. Anne Ancia, WHO’s representative in the DRC, reported from the field that the virus spread silently and rampantly across the region for several weeks before detection, leaving response teams in a sprint to catch up. As of now, Ancia confirmed, “the spread is not yet under control.”

    Without targeted vaccines or treatments, public health officials rely on the core Ebola control strategy of contact tracing and 21-day isolation to break chains of transmission. While rising case counts have raised alarm, WHO officials note the current increase is actually a positive sign that improved surveillance systems are working to uncover the true scale of the outbreak, rather than evidence of a sudden acceleration in new spread.

    Neighboring Uganda has so far avoided sustained community spread, with the WHO reporting a stable situation: just two confirmed cases in travelers who crossed from the DRC, and one death. Intense contact tracing efforts are credited with halting further spread in the country.

    Internationally, two U.S. citizens with links to the outbreak have been evacuated for care: one who tested positive was moved to Germany for treatment, while a second high-risk contact was transferred to the Czech Republic. The global risk level for the outbreak remains low, with regional risk assessed as high, per the WHO’s updated classification.

    Abdi Rahman Mahamud, the WHO’s director of emergency alert and response, explained the upgrade to very high risk for the DRC stemmed from three key factors: the severe threat to human health, the high potential for rapid spread, and the limited current response capacity on the ground. “The potential of this virus spreading rapidly is very high, and that changed the whole dynamic,” Mahamud noted.

    To address the gap in treatments, the WHO has fast-tracked plans for clinical trials of existing experimental drugs. The agency’s technical advisory group has prioritized two monoclonal antibodies — Regeneron’s 3479 and Mapp Biopharmaceutical’s MBP134 — for testing. It has also recommended evaluating the oral antiviral obeldesivir as a post-exposure preventive treatment for high-risk contacts. WHO chief scientist Sylvie Briand said the drug shows promise for preventing infected contacts from developing symptomatic disease.

    For vaccines, the existing widely approved Ervebo vaccine only targets the Zaire strain of Ebola, with very little evidence that it provides cross-protection against Bundibugyo. While work on a Bundibugyo-specific vaccine has begun, no doses are currently available for clinical trials, and development would likely take six to nine months even if the project is prioritized. Another candidate vaccine targeting the strain, built using the ChAdOx platform, is currently in production but has not yet completed animal testing required to move forward with human trials.

  • Ebola risk raised to ‘very high’ in DR Congo

    Ebola risk raised to ‘very high’ in DR Congo

    The World Health Organization has escalated its public health risk assessment for the ongoing Ebola outbreak in the Democratic Republic of the Congo, raising the national-level threat from “high” to “very high” in an official update released Friday.

    During a press briefing in Geneva, WHO Director-General Dr. Tedros Adhanom Ghebreyesus outlined the tiered risk framework: while the outbreak poses a very high danger within DR Congo’s borders, it carries a high risk for the broader African region, and remains a low risk at the global scale. The WHO had already declared a Public Health Emergency of International Concern (PHEIC) for the outbreak earlier this week, though it stopped short of classifying the event as a pandemic.

    The outbreak is driven by Bundibugyo, an uncommon strain of Ebola that currently has no licensed, widely available vaccine, and claims the lives of roughly one out of every three people it infects. As of the latest update, the outbreak has recorded 750 suspected cases and 177 suspected deaths across DR Congo, with 82 confirmed cases and seven confirmed fatalities. The virus has already spread beyond DR Congo’s borders: neighboring Uganda has reported two confirmed cases, linked to travelers from the affected DR Congo region, including one death. WHO officials noted that the situation in Uganda currently remains stable.

    Unlike more common Ebola variants, the rarity of the Bundibugyo strain has left public health responders with far fewer established countermeasures to slow transmission, even though it is slightly less deadly than other Ebola types. Like all Ebola viruses, Bundibugyo originates in wild animal populations, most commonly fruit bats, and typically spills over to humans when individuals handle or consume contaminated bushmeat.

    Compounding the public health challenge, persistent violence and instability in the conflict-affected eastern region of DR Congo has severely hampered outbreak response efforts. Dr. Tedros emphasized that building community trust is critical to containing the spread, noting a recent incident where angry relatives set fire to a local hospital after health workers declined to release an Ebola patient’s body over fears of viral contamination.

    Amid the growing risk, research teams are racing to develop targeted vaccines for the strain. A team of scientists at the University of Oxford in the United Kingdom is advancing a candidate vaccine that could be ready for human clinical trials in as little as two to three months. There is no guarantee the candidate will prove effective, however, as rigorous preclinical animal testing and human trials will be required to confirm safety and efficacy. A second experimental vaccine candidate is also in development, but that candidate is not expected to be ready for testing for six to nine months.

  • UK scientists developing new Ebola vaccine that could be ready in months

    UK scientists developing new Ebola vaccine that could be ready in months

    A rapidly escalating Ebola outbreak in the Democratic Republic of Congo (DRC), driven by a rare, untreatable strain of the virus, has spurred urgent vaccine development work from a team of researchers at the University of Oxford, with the candidate potentially ready for field deployment within months.

    The ongoing outbreak, centered in northeastern DRC, has already been linked to 750 suspected cases and 175 confirmed deaths, according to latest outbreak tracking data. The pathogen at the center of the crisis is Bundibugyo, an understudied Ebola species that has only caused two recorded outbreaks in the last 20 years and has no licensed, proven vaccine currently available. The virus kills roughly one-third of all people it infects, making swift containment a top global health priority.

    In response to the crisis, the World Health Organization (WHO) has upgraded the risk level of the outbreak from “high” to “very high” within DRC, with regional risk across central Africa also elevated to “high.” International risk remains low, however, and the WHO declared a Public Health Emergency of International Concern (PHEIC) over the outbreak over the weekend, explicitly noting that the event does not rise to the level of a pandemic.

    Oxford’s vaccine candidate leverages the same ChAdOx1 platform the university’s vaccine group refined during the global COVID-19 pandemic – a flexible, easily adaptable genetic vaccine technology that can be rapidly modified to target new pathogens. During the COVID response, the platform was loaded with coronavirus genetic material; for this Ebola candidate, it has been reconfigured to carry genetic code from the Bundibugyo strain.

    The platform relies on a modified chimpanzee common cold virus, genetically edited to be safe for human use, that delivers Bundibugyo genetic material to human cells. This trains the immune system to recognize and neutralize the actual Ebola virus if exposure occurs, without causing Ebola infection or symptomatic disease. Preclinical animal testing for the new candidate is already underway at Oxford’s facilities, and the Serum Institute of India has been pre-positioned to scale up mass manufacturing as soon as the university provides clinical-grade vaccine material.

    Professor Sarah Lambe, head of vaccine immunology at the Oxford Vaccine Group, emphasized that speed is the top priority for the project. “People are worried about this outbreak, generally, you prepare for the worst case scenario – hopefully contact tracing and quarantine is all that’s needed, but we can’t take our foot off the gas,” Lambe told BBC News. Once the research team delivers initial starting material to the Serum Institute, Lambe noted that the manufacturer can ramp up production both quickly and at large scale. The WHO projects that the candidate could be ready for human clinical trials in affected regions within two to three months.

    This outbreak poses unique challenges to global health responders because of the rarity of the Bundibugyo strain. Of the six known Ebola species, only three are known to cause large human outbreaks, and Bundibugyo had not been detected in more than a decade prior to this event – its last outbreak occurred in DRC in 2012, following an initial 2007 outbreak in Uganda. While existing effective vaccines are available for the more common Zaire Ebola strain, none have been approved for Bundibugyo. A separate experimental Bundibugyo candidate is also in development, but that effort is not expected to produce testable doses for another six to nine months, making Oxford’s accelerated timeline a critical asset for outbreak response.

    If authorized, the vaccine will not be deployed in mass public vaccination campaigns like COVID-19 vaccines. Instead, it will be used in the targeted ring vaccination strategy standard for Ebola outbreaks, which prioritizes immunization for people at highest exposure risk: close contacts of confirmed cases, and frontline healthcare workers treating infected patients. The Oxford team had already been working on related vaccine candidates for other dangerous filoviruses, including Sudan ebolavirus and Marburg virus, prior to this outbreak, allowing them to adapt their work rapidly to address the new Bundibugyo emergency.

  • WHO chief says Ebola outbreak in Congo is ‘spreading rapidly’ and upgrades risk assessment

    WHO chief says Ebola outbreak in Congo is ‘spreading rapidly’ and upgrades risk assessment

    GENEVA, Switzerland – In a stark update delivered to reporters on Friday, World Health Organization Director-General Tedros Adhanom Ghebreyesus announced a troubling escalation of the ongoing Ebola outbreak in the Democratic Republic of the Congo, raising the national risk assessment from high to the most severe tier of “very high” amid evidence of accelerating transmission.

    Tedros clarified that while the domestic risk has worsened, the threat of regional spillover still holds at a high level, and the global risk of widespread Ebola spread remains categorized as low. Official counts place the number of confirmed cases at 82, with seven confirmed fatalities recorded so far, but the WHO leader emphasized that the true scale of the epidemic far outpaces these confirmed numbers. Currently, more than 750 additional cases are classified as suspected, with 177 suspected deaths linked to the outbreak across affected areas of the country.

    Neighboring Uganda has so far avoided widespread community transmission, with the situation there remaining classified as stable. Two confirmed Ebola cases have been recorded in the country, both tied to travel from the DRC, and one of those patients has died.

    The rapidly deteriorating situation has prompted immediate action from the global humanitarian community. Earlier on Friday, the United Nations confirmed it had disbursed $60 million from its Central Emergency Response Fund, a reserve pool of emergency funding designated to speed up outbreak response efforts across the DRC and the broader Great Lakes region. The United States also announced a pledge of $23 million in new funding to support response operations in both the DRC and Uganda, alongside a plan to finance the construction of up to 50 new Ebola treatment clinics across affected zones in both countries.

    Notably, Ugandan health authorities have publicly stated that they have no knowledge of planned U.S.-funded treatment centers being established within their borders, creating a small point of discrepancy in the announcement of international support.

  • Rwanda embraces TCM to aid healthcare

    Rwanda embraces TCM to aid healthcare

    Nestled in the heart of East Africa, the “Land of a Thousand Hills” Rwanda draws visitors with its sweeping green mountain slopes, but this same dramatic terrain creates unique public health challenges for its population. For millions of Rwandans, daily life requires traversing steep, winding mountain paths for hours at a time, a routine that gradually wears down joints, muscles and musculoskeletal health over years.

  • Africa summit in India postponed over Ebola outbreak fears

    Africa summit in India postponed over Ebola outbreak fears

    A high-stakes diplomatic gathering intended to strengthen ties between India and the entire African continent has been called off at the eleventh hour, derailed by the spreading Ebola outbreak currently impacting the Democratic Republic of Congo and Uganda. The fourth iteration of the India-Africa Forum Summit, which was slated to take place in New Delhi between May 28 and 31 after more than a decade since the last convening, will be rescheduled for a later date, according to a joint statement released Thursday by the Indian government and the African Union.

    The joint announcement cited the rapidly worsening public health crisis unfolding across central Africa as the core reason for the delay, noting that a new confirmed date for the summit will be made public once the outbreak is under control. This decision comes just days after the World Health Organization (WHO) upgraded the current outbreak to the highest level of global alert: a Public Health Emergency of International Concern (PHEIC).

    As of the latest WHO update, the outbreak has already recorded 600 suspected cases and 139 suspected deaths across affected regions. To date, all reported infections have been restricted to the African continent, but public health experts have warned that this outbreak presents unique and unprecedented challenges. Unlike previous Ebola events, the current outbreak is driven by a rare strain of the virus for which no licensed vaccine currently exists, and the epicenter of the spread is located in a conflict-impacted region, complicating rapid response and containment efforts.

    Ebola is a severe, often fatal viral illness that originates in animal populations, most commonly fruit bats. Spillover into human populations typically occurs when humans handle or consume infected wild animals. After an incubation period ranging from two to 21 days, symptoms emerge abruptly, beginning with flu-like indicators including fever, headache, and fatigue. As the virus progresses, patients develop severe vomiting and diarrhea, often progressing to organ failure. A subset of patients also experience internal and external bleeding. The virus spreads between humans through direct contact with infected bodily fluids, such as blood or vomit.

    Historically, Ebola outbreaks were small and easily contained to remote, sparsely populated rural areas. But experts note that accelerating urbanization has pushed growing human populations closer to the natural reservoirs of the Ebola virus, steadily increasing the risk of future spillover events and large-scale outbreaks.

    Even though no confirmed Ebola cases have been detected within India’s borders to date, national health authorities have moved quickly to implement preventive measures. On Thursday, India’s Directorate General of Health Services released an official public health advisory for all passengers arriving from or transiting through Ebola-affected nations. The advisory directs travelers to immediately contact airport health officials and seek urgent medical care if they develop any characteristic Ebola symptoms within 21 days of travel, or if they have had close direct contact with a confirmed or suspected infected person.

  • ‘Filter of fantasy’: Japan trials anime therapy to treat depression

    ‘Filter of fantasy’: Japan trials anime therapy to treat depression

    Across the globe, mental health care systems are grappling with persistent barriers to access — from deep-rooted social stigma to widespread discomfort with opening up to human therapists. In Japan, where cultural norms have long kept rates of formal psychological help-seeking far lower than in Western nations, a team of researchers is testing an unconventional solution: turning the world of Japanese anime into a therapeutic tool to reach underserved groups struggling with depression.

    The brainchild of psychiatrist Francesco Panto, a researcher based at Yokohama City University, the experimental approach draws from Panto’s own personal experience with anime as a lifeline during adolescence. Growing up as a queer teen in rural Sicily, Panto faced rigid cultural stereotypes around gender identity and self-expression that left him feeling isolated. It was through popular titles like *Final Fantasy* that he found male protagonists who defied narrow gender norms, resonating with his own identity and offering life-changing emotional support. “They were so masculine and cool, but in their own way,” Panto recalled of the characters that shaped his understanding of self. That experience led him to wonder if anime could do the same for others, particularly those too intimidated to reach out for traditional mental health care.

    Panto’s six-month pilot study of what he calls “character-based counselling” wrapped up in March, testing the core hypothesis that a “filter of fantasy” can ease anxiety for people navigating mental health struggles and help them open up about their challenges. For the trial, his team designed six custom anime avatars based on iconic Japanese manga archetypes, each crafted with a subtle backstory tied to common mental health struggles: one character, Kuroto Nagi, lives with bipolar traits, while others navigate post-traumatic stress disorder, anxiety, and alcohol use disorder. Rather than framing these struggles explicitly upfront, the avatars were designed to feel approachable and fun, allowing participants to connect with them on their own terms. Each participant was able to select the avatar that felt most aligned with their own experience, and counselling sessions were delivered online by a licensed psychologist who appeared to participants as the chosen avatar, with a digitally modified voice to match the character.

    The trial recruited 20 participants aged 18 to 29 who were already experiencing symptoms of depression. Researchers tracked participants’ physiological markers including heart rate and sleep patterns to measure changes in their mental health over the course of the program, with the primary goal of this first phase being to test whether the approach is feasible for larger-scale trials. Already, early anecdotal feedback from participants suggests the model strikes a chord with many who avoid traditional therapy. One 24-year-old anime fan and game developer, who joined the study after connecting with an avatar described as “searching for true strength,” noted that the concept immediately felt relevant to their own unaddressed struggles: “That made me feel like it might help me get closer to the answer to my own problems,” they said. For many anime fans, the medium has already offered life-changing emotional support: the participant added that anime has long given them the “will to live, seeing characters who are full of life as they work hard toward their dreams.”

    This trial is just one of dozens of emerging interventions targeting Japan’s growing unmet mental health needs, particularly for people experiencing ikizurasa — a Japanese term describing the profound struggle of feeling unable to cope with societal expectations and survive in everyday life. As assistant professor Mio Ishii, who co-leads the project, explained, large swathes of young people in Japan are unable to attend school or maintain employment due to untreated mental health struggles, and stigma around seeking care remains a crippling barrier. Data from 2022 cited by the World Economic Forum illustrates the scale of this gap: just 6% of people in Japan have ever accessed psychological counselling for mental health concerns, compared to far higher rates in the United States and Western Europe.

    Panto and his team are already exploring future expansions of the model, including the possibility of delivering anime-based therapy entirely through artificial intelligence, eliminating the need for a human psychologist to mediate sessions and making the tool far more accessible at scale. Outside experts not affiliated with the trial have praised the approach for addressing key gaps in traditional care. Jesus Maya, a family therapy specialist at the University of Seville, noted that integrating pop culture mediums like anime into treatment can remove significant barriers to emotional expression: “It can facilitate the expression of emotions… (and) identification and communication between the patient and the therapist,” he said.

    For the research team, the potential impact extends far beyond Japan. Ishii says she hopes the model will one day provide an accessible low-stigma option for people of all ages across the globe, wherever cultural barriers keep people from seeking the help they need. “Because usually people have stigmas and psychological barriers to ask for help about their mental health,” she said. “But anime or technology can decrease them.” The team is currently analyzing pilot trial data, with results expected to guide future larger-scale studies on the effectiveness of anime therapy for reducing depression symptoms.

  • WHO warns conflict, displacement hastening spread of Ebola

    WHO warns conflict, displacement hastening spread of Ebola

    A growing Ebola outbreak caused by the rare Bundibugyo virus strain is facing severely hindered containment efforts in the eastern Democratic Republic of the Congo (DRC), driven by ongoing armed conflict and mass population displacement, the World Health Organization (WHO) has warned. In one of Central Africa’s most unstable regions, persistent insecurity, unregulated population movement and already overburdened health systems have ground critical surveillance and emergency response operations to a near halt.

    Speaking at a Wednesday press briefing, WHO Director-General Tedros Adhanom Ghebreyesus detailed the rapid deterioration of security conditions in the area. “Conflict has intensified since late 2025, and fighting has escalated significantly over the past two months, with over 100,000 people newly displaced,” he said. Adding to the risk, the affected region is a major mining hub marked by constant cross-community and cross-border population movement that creates ideal conditions for the virus to spread further.

    The outbreak has already been categorized as a Public Health Emergency of International Concern (PHEIC), the WHO’s highest alert level. Official counts stand at 51 confirmed cases and nearly 600 suspected cases across the DRC and neighboring Uganda, but WHO officials estimate the actual scope of the epidemic is far larger than current reporting indicates.

    Insecurity in DRC’s Ituri Province has completely upended routine healthcare delivery and disease tracking infrastructure, Tedros explained. Health facilities cannot operate effectively amid active combat, and hundreds of healthcare workers have been forced to flee alongside displaced civilian communities. This has gutted the region’s already limited capacity to detect new infections and roll out targeted response measures.

    Mohamed Yakub Janabi, WHO Regional Director for Africa, noted that outbreak detection in conflict-riven remote areas faces inherent structural barriers. Effective disease surveillance depends entirely on three core pillars: reliable community reporting, fully operational local health facilities, and timely access to laboratory testing. None of these are currently functional in much of eastern DRC, he added.

    “Surveillance systems rely on a combination of community reporting, local health facilities, lab confirmation, and partnership,” Janabi said, emphasizing that the WHO’s mandate is to reinforce national health authorities rather than replace their leadership in the response.

    Even when samples are collected, logistical hurdles and limited local diagnostic capacity create dangerous delays. Currently, test samples from Ituri must be transported more than 1,700 kilometers to the DRC capital Kinshasa for confirmation, extending the window for the virus to spread between confirmed cases.

    WHO officials also confirmed that healthcare-associated transmission has already been documented, including confirmed infections among frontline healthcare workers. This development underscores the urgent need to rapidly scale up infection prevention and control protocols across all care facilities in the region.

    Lucille Blumberg, an epidemiologist and former deputy director of South Africa’s National Institute for Communicable Diseases, called for an immediate ramp-up of core response measures: enhanced active surveillance, rapid contact tracing, enforced targeted quarantine protocols, and expanded protective equipment and support for frontline health workers and affected communities.

    Blumberg added that the ongoing outbreak lays bare a critical unmet need for additional international resources and support. Local authorities are already struggling to maintain routine essential health services for conditions including tuberculosis, malaria, and maternal and child healthcare in conflict-affected regions, even as they confront the new Ebola emergency.

  • US-bound plane diverts to Canada after person from Ebola-hit region boards ‘in error’

    US-bound plane diverts to Canada after person from Ebola-hit region boards ‘in error’

    A transatlantic commercial flight traveling from Paris to Detroit was forced to make an unscheduled diversion to Montreal, Canada, after airline staff incorrectly allowed a passenger who had recently traveled from the Ebola-stricken Democratic Republic of Congo (DRC) to board the aircraft, according to official statements. U.S. Customs and Border Protection (CBP), the agency that oversees U.S. border entry rules, confirmed to the BBC that the passenger should never have been allowed onto the Air France jet under current public health entry restrictions designed to curb the spread of the deadly virus. The ongoing Ebola outbreak across central Africa has already claimed nearly 140 lives, with health officials documenting more than 600 suspected infections across affected regions. As of the report’s release, authorities have not released key details about the passenger, including whether they were displaying visible Ebola symptoms, or the exact date of their most recent stay in the DRC. Air France later verified the diversion to U.S. media outlets, confirming that the plane was rerouted to Montreal Pierre Elliott Trudeau International Airport at the explicit request of U.S. public health and border authorities, after the Congolese passenger was formally denied entry to the United States. “Air France boarded a passenger from the Democratic Republic of Congo in error on a flight to the United States,” CBP said in an official statement. The agency added that it acted quickly to block the flight from landing at its intended destination, Detroit Metropolitan Wayne County Airport, prompting the 500-mile (800-kilometer) diversion north to Canadian soil. To reduce the risk of Ebola importation, the U.S. currently enforces strict entry rules: non-U.S. passport holders who have visited the DRC, South Sudan, or Uganda in the 21 days prior to travel are barred from entering the country. U.S. citizens and legal permanent residents who have traveled to these three countries are only allowed to enter through Washington-Dulles International Airport in Virginia, where they undergo mandatory enhanced public health screening. The World Health Organization (WHO) has already designated this current Ebola outbreak a Public Health Emergency of International Concern, the highest global alert level for infectious disease events. The U.S. Centers for Disease Control and Prevention (CDC) has noted that the overall risk of Ebola spreading widely within the U.S. remains relatively low, but the agency has still moved to implement layered precautionary measures to stop the virus from crossing U.S. borders. To date, one American has tested positive for Ebola in this outbreak: a physician who was working with a medical missionary organization in the DRC. He is currently receiving treatment in a specialized isolation ward at a hospital in Germany. On Wednesday, WHO officials added another layer of context to the outbreak, confirming that the specific variant driving the current outbreak—the Bundibugyo strain—does not currently have a licensed vaccine available for widespread use. According to the agency’s timeline, it could take as long as nine months before a targeted vaccine for this strain is developed and cleared for deployment. The incident has drawn attention to the challenges of enforcing cross-border public health measures during a global infectious disease emergency, highlighting how even a single administrative error can trigger major disruptions to international air travel.

  • Gonorrhoea and syphilis hit record levels in Europe

    Gonorrhoea and syphilis hit record levels in Europe

    Newly released surveillance data from the European Centre for Disease Prevention and Control (ECDC) has revealed an alarming public health crisis across the continent: rates of two major bacterial sexually transmitted infections (STIs), gonorrhoea and syphilis, have reached their highest levels in more than a decade in 2024. The official figures paint a stark picture of accelerating transmission, with confirmed gonorrhoea cases climbing to 106,331 — a staggering 303% jump from 2015 levels. Over the same nine-year period, syphilis diagnoses more than doubled to hit 45,557 in 2024.

    ECDC officials have identified growing gaps in routine STI testing and prevention services as a key contributing factor to this explosive surge, and are calling for immediate coordinated action from public health bodies across the region to reverse the trend. Bruno Ciancio, head of ECDC’s Directly Transmitted and Vaccine-Preventable Diseases unit, emphasized the serious long-term health risks associated with undiagnosed STIs. “These infections can cause severe complications, such as chronic pain and infertility, and in the case of syphilis, permanent damage to the heart or nervous system,” Ciancio explained. He added that even more concerning, cases of congenital syphilis — which occurs when an infected mother passes the infection to her newborn during childbirth, often leading to lifelong health complications — have nearly doubled between 2023 and 2024.

    Despite the rising caseload, Ciancio noted that basic protective measures remain effective at reducing transmission risk: “Protecting your sexual health remains straightforward. Use condoms with new or multiple partners, and get tested if you have symptoms.”

    Among the 31 European countries participating in the ECDC surveillance program, Spain reported the highest absolute number of confirmed cases for both infections in 2024, recording 37,169 gonorrhoea cases and 11,556 syphilis cases. The data also highlights stark disparities in infection rates across population groups: men who have sex with men remain the most disproportionately affected demographic, accounting for the sharpest long-term increases in both gonorrhoea and syphilis transmission. Public health experts also flagged a notable surge in syphilis cases among heterosexual women of reproductive age, a trend that directly ties to the rise in congenital syphilis diagnoses.

    While gonorrhoea and syphilis continue to spread at unprecedented rates, the data offers one small point of relief: chlamydia, the most commonly reported bacterial STI across Europe, has seen a 6% drop in confirmed cases since 2015, falling to 213,443 total diagnoses in 2024.

    The United Kingdom withdrew from the ECDC surveillance program following Brexit, but the UK government publishes independent annual data for England. Figures released by the UK Health Security Agency in December 2024 show the same upward STI trend playing out across the country: England recorded 71,802 gonorrhoea cases and 9,535 syphilis cases in 2024, alongside 168,889 chlamydia diagnoses. In response to a record 85,000 gonorrhoea cases reported in 2023, the UK rolled out a national gonorrhoea vaccination program in 2025 to curb transmission.

    Public health officials stress that many STIs can progress without obvious symptoms, making routine testing critical for early intervention. For gonorrhoea, common symptomatic presentations include pelvic or urinary pain, abnormal genital discharge, and genital inflammation, though a large share of infections are asymptomatic. The UK’s National Health Service (NHS) notes that infection can be prevented through consistent, correct condom use and vaccination for eligible groups. Syphilis symptoms, which often go unnoticed in early stages, include painless sores on the genitals or mouth, a non-itchy rash on the palms of the hands or soles of the feet, patchy hair loss, and flu-like systemic symptoms; symptoms often fade temporarily even as the infection remains active in the body. Like gonorrhoea, syphilis is preventable through condom use and fully treatable with common antibiotic regimens when caught early. Without prompt treatment, however, both infections can cause irreversible chronic health damage.